Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

zoster vaccine

Brand and Other Names: SHINGRIX
Mechanism of Action:

The risk of developing HZ, which increases with age and with immunosuppression due to disease and/or therapy, appears to be related to a decline in varicella zoster virus (VZV)-specific immunity. SHINGRIX was shown to boost VZV-specific immune response, which is thought to be the mechanism by which it protects against zoster disease.

Indications:

SHINGRIX is a vaccine indicated for prevention of herpes zoster (HZ) (shingles.

Route: intramuscularly
Dose:

Two doses (0.5 mL each) administered intramuscularly according to the following schedules:

A first dose at Month 0 followed by a second dose administered 2 to 6 months later.
For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule: A first dose at Month 0 followed by a second dose administered 1 to 2 months later.
Adverse Reactions:

Pain, redness, swelling at sight of injections. Myalgia, fatigue, headache,shivering, fever.

Contraindication:

Do not administer SHINGRIX to anyone with a history of a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine or after a previous dose of SHINGRIX

Warnings and Precautions:

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of SHINGRIX.  Syncope (fainting) can be associated with the administration of injectable vaccines, including SHINGRIX. Syncope can be accompanied by transient neurological signs such as visual disturbance, paresthesia, and tonic-clonic limb movements. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.

Description:

SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) is a sterile injectable suspension for intramuscular use. The vaccine is supplied as a vial of lyophilized recombinant varicella zoster virus surface glycoprotein E (gE) antigen component, which must be reconstituted at the time of use with the accompanying vial of AS01B adjuvant suspension component. The lyophilized gE antigen component is presented in the form of a sterile white powder. The AS01B adjuvant suspension component is an opalescent, colorless to pale brownish liquid supplied in vials.

See package insert for full prescribing information.